the aid library

LIST OPTIONS

Filter

1086

Sort by:

Direction:

Download (129)

View PDF (62)

Financing for Sustainable Development Report 2022

Inter-agency Task Force on Financing for Development United Nations (UN) (2022) CC

The 2022 Financing for Sustainable Development Report identifies a “great finance divide” as a main driver of the divergent recovery. Developed countries were able to borrow record sums at ultra-low interest rates to support their people and economies, but the pandemic response and investment in... more

Download (49)

View PDF (50)

Audited Financial Statements for the year ended 31 December 2020

World Health Organization (WHO) World Health Organization (WHO) (2021) CC

WHO’s total revenue in 2020 was US$ 4299 million and total expenses were US$ 3561 million, resulting in a surplus of US$ 824 million, which includes finance revenue (e.g. interest and investment income) of US$ 86 million, representing increases of 38% and 15% in revenue and expenses respectively. ... more

Download (51)

View PDF (233)

An analysis of funding patterns in development assistance for mental health: who, when, what, and where

Gribble RSF, Liese BH, Wickremsinhe MN Global Mental Health (2021) C1

Background: Mental health has recently gained increasing attention on global health and development agendas, including calls for an increase in international funding. Few studies have previously characterized official development assistance for mental health (DAMH) in a nuanced and differentiated ma... more

Download (49)

View PDF (50)

Draft Proposed programme budget 2022–2023: Building forward better

World Health Organization (WHO) World Health Organization (WHO) (2021) CC

The development of this draft Proposed programme budget 2022–2023 comes at a unique moment for WHO. The world is in the grip of the coronavirus disease (COVID-19) pandemic and faces health, social and economic consequences on an unprecedented scale. Although it is not known when the COVID-19 pande... more

Download (73)

View PDF (158)

Information Note: Disability and Inclusion in MHPSS - IASC Reference Group on Mental Health and Psychosocial Support in Emergency Settings (January 2024)

Inter-Agency Standing Committee (2024) C1

This document contains guidance for strengthening the disability inclusiveness of MHPSS responses and programmes in emergency settings. It is intended to supplement the IASC Guidelines on Mental Health and Psychosocial Support in Emergency Settings (2007). Overall Objective To consider and add... more

Download (83)

View PDF (69)

WHO's Health Emergency Appeal 2024

World Health Organization WHO (2024) C_WHO

In 2024, we need US$1.5 billion to provide live-saving health care to millions of people in emergencies. An alarming combination of conflict, climate-related threats and increasing economic hardship mean an estimated 166 million people require health assistance.

Download (60)

View PDF (61)

Development Co-operation Report 2020

OECD (2020) CC

The annual Development Co-operation Report brings new evidence, analysis and ideas on sustainable development to members of the OECD Development Assistance Committee (DAC) and the international community more broadly. The objectives are to promote best practices and innovation in development co-ope... more

Download (176)

View PDF (247)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (51)

View PDF (56)

World Humanitarian Data and Trends 2018

OCHA Health Affairs (2018) C2

World Humanitarian Data and Trends presents global- and country-level data-and-trend analysis about humanitarian crises and assistance. Its purpose is to consolidate this information and present it in an accessible way, providing policymakers, researchers and humanitarian practitioners with an evid... more

Download (66)

View PDF (57)

Global Trends and Prospects

United Nations Conference on Trade and Development (2023) CC

According to most recent data, the world economy grew by 3.1 per cent in 2022. To many, the rebound suggested that a soft landing was possible in 2023, and that the key problems of the year 2022 – rising prices, supply-chain disruptions and recession risks – have been addressed. As a result, t... more

Download (141)

View PDF (115)

Strengthening rehabilitation in health emergency preparedness, readiness, response and resilience: policy brief

World Health Organisation (WHO) (2023) C_WHO

Strengthening rehabilitation in health emergency preparedness, response, and resilience: policy brief outlines the evidence for rehabilitation in emergencies and the need for greater preparedness of rehabilitation services. It shows how existing guidelines support the integration of rehabilitation i... more

Download (80)

View PDF (124)

Contingency Fund for Emergencies 2022 annual report Enabling quick action to save lives

World Health Organisation (WHO) (2023) C_WHO

The Contingency Fund for Emergencies (CFE) provides WHO with rapid and flexible resources to respond to disease outbreaks and other health emergencies. The annual report provides an overview of the use and impact of the Fund over the previous year.

Download (140)

View PDF (159)

Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors
recommended

World Health Organisation (WHO) (2023) C_WHO

The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health sys... more

Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors recommended

Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors
recommended